Faculty Directory
- Name
- Bo Hyun KIM, M.D., Ph.D.(adjunct professor)
- Faculty Appointment
(title, department)
- Associate Professor, Department of Cancer Biomedical Science, NCC-GCSP
- Area of Expertise
- Hepatology
- E-mail
- bohkim@ncc.re.kr
- Work Experience
- Senior Scientist, Common Cancer Branch, Research Institute, National Cancer Center (2017-Present)
Senior Scientist, Liver and Pancreatobiliary Cancer Branch, National Cancer Center (2015-2017)
Specialist, Department of Internal Medicine, National Cancer Center (2012-Present)
Specialist, Center for Liver Cancer, National Cancer Center (2012-Present)
- Educational Background
- M.D, Hanyang University College of Medicine (1996-2002)
M.S, Seoul National University Graduate School of Medicine (2007-2009)
Ph.D., Seoul National University Graduate School of Medicine (2009-2011)
- Research Interests
-
- International Collaboration
-
- Achievements
- 2017 SCI Temporal Improvement in Survival of Patients with Hepatocellular Carcinoma in a Hepatitis B Virus-Endemic Population: Journal of Gastroenterology and Hepatology. 33(2):475~483 (3.452)
2017 SCI-E Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma: Oncotarget. 9(3):4034~4043 (5.168)
2017 기타 Epidemiology of liver cancer in South Korea.: Clinical and molecular hepatology.. Online:Published (0)
2017 SCI Risk of diabetes in viral hepatitis B or C patients compared to that in noninfected individuals in Korea, 2002-2013: A population-based cohort study.: Journal of Viral Hepatitis. :1~7 (4.122)
2017 SCI-E Population-based Prevalence, Incidence, and Disease Burden of Autoimmune Hepatitis in South Korea: Plos One. 12(8):e0182391~e0182391 (2.806)
2017 SCI-E Noncirrhotic hepatocellular carcinoma: etiology and occult hepatitis B virus infection in a hepatitis B virus-endemic area: Therapeutic advances in gastroenterology. 10(7):529~536 (3.648)
2016 SCI A Model Predicting Survival of Patients with Recurrent or Progressive Hepatocellular Carcinoma: The MORE Score.: Journal of gastroenterology and hepatology.. 32(3):651~658 (3.322)
2016 SCI Risk-adapted simultaneous integrated boost-proton beam therapy (SIB-PBT) for advanced hepatocellular carcinoma with tumour vascular thrombosis: Radiotherapy and Oncology. 122(1):122~129 (4.817)
2016 SCI-E A New Cell Block Method for Multiple Immunohistochemical Analysis of Circulating Tumor Cells in Patients with Liver Cancer.: Cancer research and treatment. 48(4):1229~1242 (4.245)
2015 SCI Population-based epidemiology of primary biliary cirrhosis in South Korea: Alimentary Pharmacology and Therapeutics. 43(1):154~162 (5.727)
2015 SCI Incidence, prevalence and complications of Budd-Chiari syndrome in South Korea: a nationwide, population-based study: Liver international. Online:Published (4.85)
2015 SCI Prognostic indicators for radiotherapy of abdominal lymph node metastases from hepatocellular carcinoma: Strahlentherapie und Onkologie. 191(11):835~844 (2.914)
2015 SCI Downregulation of discoidin domain receptor 2 decreases tumor growth of hepatocellular carcinoma.: Journal of cancer research and clinical oncology. 141(11):1973~1983 (3.081)
2015 SCI-E Korean Version of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma (K-MESIAH).: PLoS One. Online:Published (3.234)
2015 SCI-E Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies: World Journal of Gastroenterology. 21(38):10874~10882 (2.369)
2015 SCI-E SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma: Oncotarget [electronic resource]. 6(18):16449~16460 (6.359)
2015 SCI-E 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma.: Korean journal of radiology. 16(3):465~522 (1.571)
2015 SCI Tenofovir Monotherapy versus Tenofovir plus Lamivudine or Telbivudine Combination Therapy in Treatment of Lamivudine-Resistant Chronic Hepatitis B.: Antimicrobial agents and chemotherapy. 59(2):972~978 (4.476)
2015 SCI-E Phase I Dose-Escalation Study of Proton Beam Therapy for Inoperable Hepatocellular Carcinoma.: Cancer research and treatment. 47(1):34~45 (3.318)
2014 기타 Systemic therapy for hepatocellular carcinoma: why do we keep failing?: Hepatic Oncology. 1(4):335~358 (0)
2014 SCI Simultaneous integrated boost-intensity modulated radiation therapy for inoperable hepatocellular carcinoma: Strahlentherapie und Onkologie. 190(10):882~890 (2.733)
2014 SCI Long-term outcomes of second treatment after initial transarterial chemoembolization in patients with hepatocellular carcinoma.: Liver international. 34(8):1278~1286 (4.447)
2014 SCI Validation of a model to estimate survival in ambulatory patients with hepatocellular carcinoma: a single-centre cohort study.: Liver international : official journal of the International Association for the Study of the Liver. 34(7):e317~e323 (4.447)
2014 SCI Efficacy of argon plasma coagulation in the treatment of radiation-induced hemorrhagic gastroduodenal vascular ectasia: Scandinavian Journal of Gastroenterology. 49(2):238~245 (2.329)
2013 SCI-E Outcomes of Concurrent Chemoradiotherapy versus Chemotherapy Alone for Advanced-stage Unresectable Intrahepatic Cholangiocarcinoma: Radiation Oncology. 21(8):292~292 (2.107)
2013 SCI Guggulsterone attenuates activation and survival of hepatic stellate cell by inhibiting nuclear factor kappa B activation and inducing apoptosis: Journal of Gastroenterology and Hepatology. 28(12):1859~1868 (3.325)
2013 SCI-E Recent advances in systemic chemotherapy of hepatocellular carcinoma: J Korean Med Assoc(JKMA:대한의사협회지). 11:993~1000 (0.183)
2013 SCI-E Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer: Radiation Oncology. 8(1):160~160 (2.107)
2013 SCI Clinical features of autoimmune hepatitis and comparison of two diagnostic criteria in Korea: a nationwide, multicenter study: Journal of Gastroenterology and Hepatology. 25(1):128~134 (3.325)
2012 SCI Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study.: Scandinavian journal of gastroenterology. 47:1048~1055 (2.019)
